V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330006674 | 330003427 | 1.61 | 57.4 | Curative (C) | 2016-02-13 | 2016-02-20 | CISPLATIN + RT | N | Y | 330003224 | CISPLATIN + RT |
| 330006675 | 330003427 | null | 16.8 | Disease modification (D) | 2015-06-05 | 2015-06-06 | EW Rel rEECur Topotecan/Cyclophosphamide | 02 | N | 330003224 | NOT MATCHED |
| 330006676 | 330003428 | 0.8 | 89.7 | Palliative (P) | 2013-03-13 | 2013-03-13 | NB HRNBL-1 COJEC Ind COURSE B | N | null | 330003229 | NOT MATCHED |
| 330006677 | 330003428 | 0 | 47.3 | Curative (C) | 2014-08-01 | 2016-03-12 | EW EuroEwing 2012 Arm B VC | N | N | 330003229 | NOT MATCHED |
| 330006678 | 330003429 | 1.79 | 99.9 | Adjuvant (A) | 2017-12-03 | 2017-12-03 | Cisplatin 100 + RT(H&N) 1 day | Y | Y | 330003254 | CISPLATIN + RT |
| 330006679 | 330003430 | 1.76 | null | Adjuvant (A) | null | 2017-03-18 | DOXORUBICIN | N | Y | 330003256 | DOXORUBICIN |
| 330006680 | 330003430 | 1.67 | 78.2 | Neo-adjuvant (N) | 2017-03-23 | 2017-05-31 | DOXORUBICIN | Y | null | 330003256 | DOXORUBICIN |
| 330006681 | 330003431 | 1.7 | 63.4 | Palliative (P) | 2014-10-03 | 2015-12-09 | DOXORUBICIN | N | N | 330003258 | DOXORUBICIN |
| 330006682 | 330003432 | 1.62 | 62.65 | Curative (C) | 2010-12-08 | 2013-06-07 | Mifamurtide weeks 1-12 | 02 | N | 330003276 | MIFAMURTIDE |
| 330006683 | 330003433 | 1.78 | null | Curative (C) | 2017-06-29 | 2017-08-14 | Trial Unspecified | N | N | 330003279 | TRIAL |
| 330006684 | 330003435 | 1.76 | 61 | Neo-adjuvant (N) | 2014-12-08 | 2015-05-12 | EW EuroEwing 2012 Arm B IE | 02 | N | 330003283 | TRIAL |
| 330006685 | 330007830 | 1.58 | 64.9 | Palliative (P) | 2013-04-28 | 2014-04-24 | Doxorubin 50mg/m2 | N | N | 330003283 | DOXORUBICIN |
| 330006686 | 330007830 | null | 104 | Adjuvant (A) | 2013-04-20 | 2013-10-04 | Doxorubicin 75mg/m2 | 02 | N | 330003283 | DOXORUBICIN |
| 330006687 | 330003436 | null | 76.3 | Palliative (P) | null | 2017-09-08 | METHOTREXATE | N | null | 330003309 | METHOTREXATE |
| 330006688 | 330003437 | 1.74 | 118.7 | Curative (C) | null | 2017-04-18 | Cisplatin | Y | null | 330003309 | CISPLATIN |
| 330006689 | 330003437 | 1.58 | null | Neo-adjuvant (N) | 2018-04-07 | 2018-11-16 | Trial Unspecified | 2 | N | 330003309 | TRIAL |
| 330006690 | 330003437 | null | 43.6 | Curative (C) | 2014-05-20 | 2014-05-22 | Mifamurtide weeks 13-36 | 02 | N | 330003309 | MIFAMURTIDE |
| 330006691 | 330003439 | 1.69 | 88.9 | Curative (C) | 2018-05-14 | 2018-05-14 | Mifamurtide weeks 1-12 | N | N | 330003325 | MIFAMURTIDE |
| 330006692 | 330003440 | 1.74 | 61.4 | Curative (C) | 2014-01-14 | 2014-01-14 | Trial Unspecified | 2 | Y | 330003327 | TRIAL |
| 330006693 | 330003441 | 0 | 87 | Palliative (P) | 2016-05-14 | 2016-05-15 | EW EuroEwing 2012 Arm B VDC | 2 | N | 330003329 | TRIAL |
| 330006694 | 330003442 | 0 | 81.5 | Palliative (P) | 2013-07-09 | 2013-11-14 | EW EuroEwing 2012 Arm A VAI | 2 | N | 330003334 | TRIAL |
| 330006695 | 330003442 | 1.68 | 91.8 | Neo-adjuvant (N) | null | 2016-10-15 | METHOTREXATE | N | null | 330003334 | METHOTREXATE |
| 330006696 | 330003446 | 0 | 46.2 | Neo-adjuvant (N) | null | 2013-11-24 | MIFAMURTIDE | Y | null | 330003344 | MIFAMURTIDE |
| 330006697 | 330003446 | 1.68 | 81 | Neo-adjuvant (N) | null | 2014-04-20 | METHOTREXATE | null | null | 330003344 | METHOTREXATE |
| 330006698 | 330003450 | 1.69 | 99 | null | null | 2016-01-31 | Mifamurtide weeks 1-12 | null | null | 330003348 | MIFAMURTIDE |
| 330006699 | 330007840 | 1.6 | 50.3 | Curative (C) | null | 2014-01-22 | Doxorubicin 75mg/m2 | N | null | 330003349 | DOXORUBICIN |
| 330006700 | 330003452 | 0 | 24.6 | Curative (C) | 2015-05-24 | 2015-06-08 | EW EuroEwing 2012 Arm B IE | N | N | 330003353 | TRIAL |
| 330006701 | 330003454 | 1.57 | 47 | Curative (C) | 2013-09-15 | 2013-10-11 | Cisplatin | null | null | 330003353 | CISPLATIN |
| 330006702 | 330003455 | 1.81 | 75.5 | Neo-adjuvant (N) | 2017-08-14 | 2017-08-14 | MIFAMURTIDE | 02 | N | 330003354 | MIFAMURTIDE |
| 330006703 | 330003456 | 1.7 | 60.7 | Curative (C) | 2016-09-15 | 2016-09-16 | Trial Unspecified | 02 | Y | 330003355 | TRIAL |
| 330006704 | 330003457 | 1.77 | 71 | Curative (C) | 2014-11-26 | 2016-05-04 | DOXORUBICIN | 1 | N | 330003375 | DOXORUBICIN |
| 330006705 | 330003458 | 1.78 | 55 | Neo-adjuvant (N) | 2014-06-14 | 2014-07-03 | Trial Unspecified | N | N | 330003376 | TRIAL |
| 330006706 | 330003461 | 1.7 | 74.1 | Curative (C) | 2013-08-28 | 2013-11-22 | Doxorubicin 75mg/m2 | N | N | 330003386 | DOXORUBICIN |
| 330006707 | 330003462 | null | 22.9 | Palliative (P) | 2015-02-10 | 2016-04-25 | METHOTREXATE | N | N | 330003394 | METHOTREXATE |
| 330006708 | 330003464 | 1.82 | 80.5 | null | null | 2016-12-12 | MIFAMURTIDE | N | null | 330003394 | MIFAMURTIDE |
| 330006709 | 330003466 | 1.95 | 88 | Neo-adjuvant (N) | 2015-06-14 | 2015-08-28 | Cisplatin | 02 | N | 330003396 | CISPLATIN |
| 330006710 | 330003467 | 0 | 59 | Palliative (P) | 2017-07-25 | 2017-08-02 | Trial Unspecified | null | null | 330003402 | TRIAL |
| 330006711 | 330003469 | 1.61 | 65.2 | Neo-adjuvant (N) | 2013-06-06 | 2014-02-20 | DOXORUBICIN | N | Y | 330003405 | DOXORUBICIN |
| 330006712 | 330003470 | 1.73 | 53.7 | Adjuvant (A) | 2014-01-12 | 2014-06-09 | METHOTREXATE | N | N | 330003411 | METHOTREXATE |
| 330006713 | 330003470 | null | 63.4 | Neo-adjuvant (N) | 2014-02-21 | 2014-05-03 | METHOTREXATE | null | null | 330003411 | METHOTREXATE |
| 330006714 | 330011600 | 1.68 | 96.45 | Not known (9) | 2014-03-19 | 2014-07-21 | MIFAMURTIDE | 1 | N | 330003438 | MIFAMURTIDE |
| 330006715 | 330003473 | 1.77 | 74.4 | Neo-adjuvant (N) | 2013-08-06 | 2013-08-07 | Mifamurtide weeks 1-12 | N | N | 330003451 | MIFAMURTIDE |
| 330006717 | 330011601 | null | 47.6 | Neo-adjuvant (N) | 2014-05-14 | 2014-07-25 | METHOTREXATE | 2 | Y | 330003453 | METHOTREXATE |
| 330006718 | 330011601 | 1.79 | 70.1 | Palliative (P) | null | 2016-04-12 | DOXORUBICIN | null | null | 330003453 | DOXORUBICIN |
| 330006719 | 330011601 | 1.84 | 60.8 | Adjuvant (A) | 2014-01-30 | 2014-04-11 | OST Euramos 1 Closed Trial - A | N | null | 330003453 | DOXORUBICIN |
| 330006720 | 330003475 | 1.6 | 50.4 | Neo-adjuvant (N) | null | 2016-02-04 | Trial Unspecified | 2 | N | 330003471 | TRIAL |
| 330006721 | 330003475 | null | 41.6 | Neo-adjuvant (N) | 2015-09-10 | 2016-03-03 | OST Euramos 1 Closed Trial - IE | N | N | 330003471 | TRIAL |
| 330006722 | 330003477 | 1.58 | 68 | Neo-adjuvant (N) | null | 2013-11-08 | Trial Unspecified | null | null | 330003477 | TRIAL |
| 330006723 | 330003478 | 1.8 | null | Neo-adjuvant (N) | 2016-07-27 | 2017-01-22 | METHOTREXATE | 02 | Y | 330003481 | METHOTREXATE |
| 330006724 | 330003480 | null | 62 | Neo-adjuvant (N) | null | 2013-12-15 | Trial Unspecified | 01 | N | 330003485 | TRIAL |